Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
mRNA Vaccine
Sort By
Newest First
1 / 2
1 / 2
New Integrated mRNA Offering
Building on Experience and Investing in an Integrated mRNA Offering
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-03
July 31, 2023
Custom Lipid Nanoparticle Development
The Value of a Custom Lipid Solutions Provider for mRNA Delivery
Lauren Longobardi, Ph.D.; Rima Jaber, Ph.D.; Sebastian Detlefsen, Dr.-Ing.
Evonik
PAO-11-022-CL-17
January 05, 2023
mRNA Manufacturing
Investing in the Future of mRNA Manufacturing
Esther Yoo, Ph.D.
Samsung Biologics
PAO-11-022-CL-02
November 16, 2022
mRNA Manufacturing
Overcoming Bottlenecks in mRNA Manufacturing
Pierre Catignol; Huisub Lim
Samsung Biologics
PAO-10-022-CL-04
October 24, 2022
mRNA
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-02
October 11, 2022
RNA
Closing the Developability Gap for RNA Therapeutics and Vaccines with a Fit-for-Purpose Analysis Kit
Susan Darling; Quincy Mehta
SCIEX
PAO-07-022-CL-06
July 19, 2022
Vaccine and Cell & Gene Therapies
Expanding Manufacturing Capacity to Meet Market Demand for Vaccines and Cell and Gene Therapeutics
Prof. Dr. Ulrike Fiedler
IDT Biologika
PAO-04-022-CL-02
April 13, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02
March 23, 2022
mRNA
Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects
Scott Doncaster; Marc Sauer, Ph.D.
BIOVECTRA
PAO-02-022-CL-07
March 12, 2022
Strategic Partnership
eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to Access mRNA Technologies
eTheRNA Immunotherapies NV
PR-M02-22-02
February 03, 2022
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
Mark Bamforth; Dave Stevens
Arranta Bio
PAO-01-22-R250-04
January 26, 2022
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
Mark Bamforth
Arranta Bio
PAO-11-21-CL-06
December 08, 2021
Investing in mRNA Production
Michael Wourms
Arranta Bio
PA766
November 22, 2021
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
Doug Kennedy
Arranta Bio
PAO-11-21-CL-05
November 22, 2021
mRNA Manufacturing
Integrating a Fragmented mRNA Supply Chain
Dave Stevens
Arranta Bio
PAO-11-21-CL-04
November 22, 2021
mRNA Vaccines
BIOVECTRA mRNA Vaccine and Biomanufacturing Facility Announced
BIOVECTRA
PR-M11-21-02
November 18, 2021
mRNA
Integrated Support Facilitates mRNA Product Development and Commercialization
Michael Wourms; Dave Stevens
Arranta Bio
PAO-10-21-CL-15
October 26, 2021
mRNA Vaccines
Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-Ready GMP Facility
Arranta Bio
PR-M09-21-05
September 23, 2021
Lipid Nanoparticles
Advancing Novel Therapeutics with End-to-End Lipid Nanoparticle Development and Manufacturing
Natalia Zisman
Evonik
PAO-07-21-CL-02
July 12, 2021
Partnership
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline
Aldevron
PR-M05-21-018
May 28, 2021
